Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 128

Similar articles for PubMed (Select 21558402)

1.

Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease.

Beres A, Komorowski R, Mihara M, Drobyski WR.

Clin Cancer Res. 2011 Jun 15;17(12):3969-83. doi: 10.1158/1078-0432.CCR-10-3347. Epub 2011 May 10.

2.

Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo.

Zhang P, Tey SK, Koyama M, Kuns RD, Olver SD, Lineburg KE, Lor M, Teal BE, Raffelt NC, Raju J, Leveque L, Markey KA, Varelias A, Clouston AD, Lane SW, MacDonald KP, Hill GR.

J Immunol. 2013 Nov 15;191(10):5291-303. doi: 10.4049/jimmunol.1301181. Epub 2013 Oct 11.

3.

CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity.

Beres AJ, Haribhai D, Chadwick AC, Gonyo PJ, Williams CB, Drobyski WR.

J Immunol. 2012 Jul 1;189(1):464-74. doi: 10.4049/jimmunol.1200886. Epub 2012 May 30.

4.

STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft-versus-host disease.

Laurence A, Amarnath S, Mariotti J, Kim YC, Foley J, Eckhaus M, O'Shea JJ, Fowler DH.

Immunity. 2012 Aug 24;37(2):209-22. doi: 10.1016/j.immuni.2012.05.027.

5.

Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice.

Semple K, Yu Y, Wang D, Anasetti C, Yu XZ.

Biol Blood Marrow Transplant. 2011 Mar;17(3):309-18. doi: 10.1016/j.bbmt.2010.12.710. Epub 2011 Jan 9.

6.

IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.

Koenecke C, Lee CW, Thamm K, Föhse L, Schafferus M, Mittrücker HW, Floess S, Huehn J, Ganser A, Förster R, Prinz I.

J Immunol. 2012 Sep 15;189(6):2890-6. doi: 10.4049/jimmunol.1200413. Epub 2012 Aug 6.

7.

Curcumin attenuates acute graft-versus-host disease severity via in vivo regulations on Th1, Th17 and regulatory T cells.

Park MJ, Moon SJ, Lee SH, Yang EJ, Min JK, Cho SG, Yang CW, Park SH, Kim HY, Cho ML.

PLoS One. 2013 Jun 20;8(6):e67171. doi: 10.1371/journal.pone.0067171. Print 2013.

8.

[Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice].

Cao J, Li L, Chen C, Zeng LY, Li ZY, Pan XY, Xu KL.

Zhonghua Xue Ye Xue Za Zhi. 2011 Feb;32(2):83-8. Chinese.

9.

IL-17 gene ablation does not impact Treg-mediated suppression of graft-versus-host disease after bone marrow transplantation.

Colonna L, Florek M, Leveson-Gower DB, Sega EI, Baker J, Smith AT, Negrin RS.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1557-65. doi: 10.1016/j.bbmt.2013.07.024. Epub 2013 Aug 3.

10.

Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease.

Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M, Drobyski WR.

Blood. 2009 Jul 23;114(4):891-900. doi: 10.1182/blood-2009-01-197178. Epub 2009 Jun 2.

11.

Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.

Pillai AB, George TI, Dutt S, Strober S.

Blood. 2009 Apr 30;113(18):4458-67. doi: 10.1182/blood-2008-06-165506. Epub 2009 Feb 12.

12.
13.

Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD.

Koenecke C, Czeloth N, Bubke A, Schmitz S, Kissenpfennig A, Malissen B, Huehn J, Ganser A, Förster R, Prinz I.

Eur J Immunol. 2009 Nov;39(11):3091-6. doi: 10.1002/eji.200939432.

PMID:
19750478
14.
15.

Regulation of Foxp3+ inducible regulatory T cell stability by SOCS2.

Knosp CA, Schiering C, Spence S, Carroll HP, Nel HJ, Osbourn M, Jackson R, Lyubomska O, Malissen B, Ingram R, Fitzgerald DC, Powrie F, Fallon PG, Johnston JA, Kissenpfennig A.

J Immunol. 2013 Apr 1;190(7):3235-45. doi: 10.4049/jimmunol.1201396. Epub 2013 Mar 1.

16.
17.

Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.

Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS.

Blood. 2011 Aug 25;118(8):2342-50. doi: 10.1182/blood-2010-10-313684. Epub 2011 Jul 6.

18.

Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.

Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Evers R, Chockley P, Nieves E, Sun Y, Lowler KP, Malter C, Nishimoto N, Hill GR, Reddy P.

Clin Cancer Res. 2011 Jan 1;17(1):77-88. doi: 10.1158/1078-0432.CCR-10-1198. Epub 2010 Nov 3.

19.

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.

Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, Piwnica-Worms DR, DiPersio JF.

Blood. 2010 Jul 8;116(1):129-39. doi: 10.1182/blood-2009-12-257253. Epub 2010 Apr 27.

20.

Therapeutic evaluation of ex vivo-generated versus natural regulatory T-cells in a mouse model of chronic gut inflammation.

Karlsson F, Martinez NE, Gray L, Zhang S, Tsunoda I, Grisham MB.

Inflamm Bowel Dis. 2013 Oct;19(11):2282-94. doi: 10.1097/MIB.0b013e31829c32dd.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk